Clinical Research Directory
Browse clinical research sites, groups, and studies.
Investigating a Personalized Approach to Anti-Platelet Therapy
Sponsor: Ottawa Heart Institute Research Corporation
Summary
RAPID PREVENT aims to identify if a personalized (targeted) anti-platelet strategy will reduce bleeding events when compared to the current standard anti-platelet therapy.
Official title: Reassessment of Anti-Platelet Therapy Using an Individualized Strategy With Pharmacogenomics to Refine Anti-Platelet Drugs in Vulnerable Patients to Eliminate Thrombotic and Bleeding Complications - A Cluster Randomized Pilot Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
1760
Start Date
2026-10-01
Completion Date
2029-12-28
Last Updated
2026-09-08
Healthy Volunteers
No
Conditions
Interventions
Genotyping guided therapy for anti-platelet management
Participants that are carriers of the CYP2C19 gene will receive either Ticagrelor monotherapy, or dual therapy with Ticagrelor and Aspirin. Participants that are not carriers of the CYP2C19 gene will receive either Plavix monotherapy or dual therapy with Plavix and Aspirin.
Locations (1)
University of Ottawa Heart Institute
Ottawa, Ontario, Canada